Options for treating carbapenem-resistant Enterobacteriaceae

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 479-483

  Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycoside; Carbapenem resistant Enterobacteriaceae; Colistin; Fosfomycin; Meropenem; Tigecycline

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; COLISTIN; FOSFOMYCIN; IMIPENEM; MEROPENEM; TIGECYCLINE; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL DECISION MAKING; ENTEROBACTERIACEAE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; ANALOGS AND DERIVATIVES; CLINICAL PRACTICE; DRUG COMBINATION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; STANDARDS; TREATMENT OUTCOME;

BETA-LACTAM RESISTANCE; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84927786050     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000109     Document Type: Review

References (14)

1. Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58:654-663.
2. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-2328.
3. Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multicentre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20:O117-O123.
4. Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemaseproducing K. Pneumoniae in intensive care unit. Clin Infect Dis 2013; 56:697-700.
5. Balandin Moreno B, Fernandez Simon I, Pinto Garcia V, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014; 46:175-180.
6. Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43:52-59.
7. Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 2013; 13:2619-2633.
8. McLaughlin MM, Advincula MR, Malczynski M, et al. Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. BMC Infect Dis 2014; 14:31.
9. Balkan II, Aygün G, Aydin S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 2014; 26C:51-56.
10. Di Carlo P, Gulotta G, Casuccio A, et al. KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol 2013; 13:13.
11. de Sanctis J, Teixeira L, van Duin D, et al. Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections. Int J Infect Dis 2014; 25:73-78.
12. Brust K, Evans A, Plemmons R. Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with highdose tigecycline. J Antimicrob Chemother 2014. [Epub ahead of print.]
13. van Duin D, Cober E, Richter SS, et al. Tigecycline therapy for carbapenemresistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014; doi: 10.1111/1469-0691.12714. [Epub ahead of print]
14. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. Pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-950.